Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Depressive anxiety

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    166 result(s) found for: Depressive anxiety. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2005-001606-66 Sponsor Protocol Number: OLZvsLMT-DB Start Date*: 2005-06-16
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: OLANZAPINE VS LAMOTRIGINE ADD-ON TO LITHIUM:EFFICACY ON ANXIETY SYMPTOMS IN REMITTING BIPOLAR PATIENTS
    Medical condition: EFFICACY ON ANXIETY SYMPTOMS IN REMITTING BIPOLAR PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    6.1 10057667 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000426-62 Sponsor Protocol Number: CHDR1203-E Start Date*: 2013-04-10
    Sponsor Name:Centre for Human Drug Research
    Full Title: A randomized, double blind, placebo-controlled crossover study to investigate the effects of a selective serotonergic reuptake inhibitor on resting state fMRI in healthy volunteers.
    Medical condition: healthy volunteers 'depression, anxiety'
    Disease: Version SOC Term Classification Code Term Level
    15.1 10037175 - Psychiatric disorders 10012378 Depression PT
    15.1 10037175 - Psychiatric disorders 10002855 Anxiety PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003404-12 Sponsor Protocol Number: CL2-20098-075 Start Date*: 2013-02-12
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Pharmacokinetics and safety of agomelatine in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with Depressive or Anxiety Disorder. An open-labelled, multice...
    Medical condition: Depressive or Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10057666 Anxiety disorder PT
    17.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) HU (Completed) EE (Completed) RO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020170-42 Sponsor Protocol Number: 12708A Start Date*: 2012-10-05
    Sponsor Name:H. Lundbeck A/S
    Full Title: An open-label study evaluating the Pharmacokinetics and Tolerability of Lu AA21004 in connection with multiple oral dosing of Lu AA21004 in child and adolescent patients with a DSM-IV-TRTM diagnosi...
    Medical condition: DSM-IV-TRTM diagnosed Depressive or Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10002861 Anxiety disorders and symptoms HLGT
    14.1 10037175 - Psychiatric disorders 10012401 Depressive disorders HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022460-12 Sponsor Protocol Number: MVH-03 Start Date*: 2011-03-23
    Sponsor Name:Herlev Hospital
    Full Title: The effect of melatonin on depression, anxiety, cogntive function and sleep disturbances in breast cancer patients
    Medical condition: Depression Anxiety Postoperative cognitive dysfunction Sleep disturbances
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012378 Depression LLT
    12.1 10002855 Anxiety LLT
    12.1 10009845 Cognitive disturbance LLT
    12.1 10040997 Sleep disturbances LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004006-81 Sponsor Protocol Number: LTE5376 Start Date*: 2006-06-01
    Sponsor Name:sanofi-aventis recherche&developpement
    Full Title: A double-blind, 6 to 12-month, multicenter, multinational, randomized study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of relapse / recurrence of d...
    Medical condition: patients with major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    8.0 10018105 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) FI (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-005597-67 Sponsor Protocol Number: EFC4846 Start Date*: 2006-03-29
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A (350 mg q12) in elderly patients with Major Depressive Di...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10018105 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000465-31 Sponsor Protocol Number: CannaBiD Start Date*: 2016-06-29
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression
    Medical condition: Bipolar disorder, current episode depressed
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10004936 Bipolar depression LLT
    19.0 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    19.0 10037175 - Psychiatric disorders 10026756 Manic depressive illness LLT
    19.0 10037175 - Psychiatric disorders 10026755 Manic depressive LLT
    19.0 10037175 - Psychiatric disorders 10004911 Bipolar affective disorder, depressed LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000438-21 Sponsor Protocol Number: 750201.01.035 Start Date*: 2012-10-17
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Multi-center, double-blind, placebo-controlled, randomized phase III study to prove the efficacy, safety and tolerability of Silexan (WS®1265) in patients with mixed anxiety and depressive disorder...
    Medical condition: mixed anxiety and depressive disorder (ICD-10, F41.2)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10027741 Mixed anxiety & depressive LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002007-29 Sponsor Protocol Number: 42165279MDD2001 Start Date*: 2015-11-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects with Major Depressive Di...
    Medical condition: Major Depressive Disorder Anxiety
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000370-20 Sponsor Protocol Number: 2448/2007 Start Date*: 2008-08-05
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Evaluation of pharmacokinetic and pharmacodynamic interactions between escitalopram and drugs used for the treatment of bipolar disorders.
    Medical condition: bipolar disorders
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057667 Bipolar disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003658-47 Sponsor Protocol Number: F02207 GE 3 03 Start Date*: 2006-11-21
    Sponsor Name:Pierre Fabre Médicament - IRPF
    Full Title: Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001325-27 Sponsor Protocol Number: 18314A Start Date*: 2019-12-26
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label effectiveness study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder comorbid with generalized anxiety disorder
    Medical condition: Depressive symptoms in patients with major depressive disorder (MDD) comorbid with generalized anxiety disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006121-26 Sponsor Protocol Number: 40411813DAX2001 Start Date*: 2012-06-06
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Double-Blind, Placebo-Controlled Study of JNJ-40411813 as Adjunctive Treatment to an Antidepressant in Adults with Major Depressive Disorder with Anxiety Symptoms
    Medical condition: Major Depressive Disorder with Anxiety Symptoms
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001779-35 Sponsor Protocol Number: 4 Start Date*: 2013-02-15
    Sponsor Name:University of Southampton
    Full Title: The effects of pregabalin augmentation of antidepressant drug on neuro-cognitive functioning in patients with generalized anxiety disorder
    Medical condition: Generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-002116-32 Sponsor Protocol Number: MTM-04 Start Date*: 2015-09-23
    Sponsor Name:Køge Hospital
    Full Title: The effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep disturbances in patients after acute myocardial syndrome
    Medical condition: Depression Anxiety Sleep disturbances Circadian disturbances
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10009190 Circadian dysrhythmia LLT
    19.0 100000004873 10002865 Anxiety reaction LLT
    19.0 100000004873 10040999 Sleep disturbed LLT
    19.0 100000004873 10012402 Depressive episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004005-11 Sponsor Protocol Number: ESKETINTRD2003 Start Date*: 2013-12-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)
    Medical condition: Treatment Resistant Major Depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003867-13 Sponsor Protocol Number: CL2-47445-014 Start Date*: 2016-02-15
    Sponsor Name:Institut de Recherches internationales Servier
    Full Title: Efficacy and safety of S 47445 versus placebo as adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to antidepressant therapy. A randomised, double-blind, pla...
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) SK (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-004147-33 Sponsor Protocol Number: EFC5895 Start Date*: 2007-02-21
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An Eight-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fixed Dose of SR58611A 350 mg Twice a Day in Elderly Patients with Generalized ...
    Medical condition: Generalized Anxiety Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) AT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2022-001997-70 Sponsor Protocol Number: EXCELLENCE/0421/0543v1 Start Date*: 2022-11-16
    Sponsor Name:University of Cyprus
    Full Title: Efficacy of Ketamine for the Prevention of Relapse in Patients with Opioid-Use Disorders (OUD)
    Medical condition: Methadone and buprenorphine comprise a first-line, evidence-based opioid substitution treatment (OST) for OUD patients. Unfortunately, retention and adherence to OST treatment is currently a major ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10019935 Heroin addiction LLT
    20.1 10037175 - Psychiatric disorders 10030900 Opium addiction LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CY (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA